Literature DB >> 31743477

Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis.

Colin Quinn1, Christyn Edmundson1, Nabila Dahodwala1, Lauren Elman1.   

Abstract

BACKGROUND: Validation of biomarkers of upper motor neuron (UMN) impairment in amyotrophic lateral sclerosis (ALS) requires a reliable clinical assessment of UMN findings. The Penn Upper Motor Neuron Score© (PUMNS) is a standardized measure of UMN signs in ALS. Our aims were to evaluate its intra- and inter-rater reliability, and to examine inter-item reliability as a proxy for item relatedness and scale efficiency.
METHODS: Study procedures were performed during routine clinic visits. We calculated intra and inter-rater reliability using Pearson's correlation coefficient and inter-item reliability using Cronbach's alpha.
RESULTS: PUMNS had high intra and inter-rater reliability. Total and sub-score correlation coefficients were all ≥0.96. The inter-item reliability indicated appropriate item relatedness with reasonable efficiency and sub-score correlation coefficients between 0.68 and 0.85.
CONCLUSIONS: PUMNS is a reliable measure of UMN signs in ALS and would be a useful tool in validating imaging and laboratory biomarkers of UMN injury in ALS.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  amyotrophic lateral sclerosis; biomarker; lateral sclerosis; primary; reliability; upper motor neuron

Year:  2019        PMID: 31743477     DOI: 10.1002/mus.26764

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

1.  Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis.

Authors:  Eleonora Colombo; Alberto Doretti; Francesco Scheveger; Alessio Maranzano; Giulia Pata; Delia Gagliardi; Megi Meneri; Stefano Messina; Federico Verde; Claudia Morelli; Stefania Corti; Luca Maderna; Vincenzo Silani; Nicola Ticozzi
Journal:  J Neurol       Date:  2022-10-02       Impact factor: 6.682

2.  Imaging and clinical data indicate considerable disease burden in 'probable' PLS: Patients with UMN symptoms for 2-4 years.

Authors:  Eoin Finegan; We Fong Siah; Stacey Li Hi Shing; Rangariroyashe H Chipika; Kai Ming Chang; Mary Clare McKenna; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Colette Donaghy; Siobhan Hutchinson; Russel L McLaughlin; Orla Hardiman; Peter Bede
Journal:  Data Brief       Date:  2020-09-01

3.  Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone.

Authors:  Eugenio Distaso; Giammarco Milella; Domenico Maria Mezzapesa; Alessandro Introna; Eustachio D'Errico; Angela Fraddosio; Stefano Zoccolella; Franca Dicuonzo; Isabella Laura Simone
Journal:  J Neurol       Date:  2021-03-02       Impact factor: 4.849

4.  TMEM106B Acts as a Modifier of Cognitive and Motor Functions in Amyotrophic Lateral Sclerosis.

Authors:  Arianna Manini; Antonia Ratti; Alberto Brusati; Alessio Maranzano; Isabella Fogh; Silvia Peverelli; Stefano Messina; Davide Gentilini; Federico Verde; Barbara Poletti; Claudia Morelli; Vincenzo Silani; Nicola Ticozzi
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

5.  Neurophysiological differentiation of upper motor neuron damage in neurodegenerative disorders.

Authors:  Yuichiro Shirota; Juuri Otsuka; Tatsushi Toda; Masashi Hamada
Journal:  Clin Neurophysiol Pract       Date:  2022-09-23

6.  Longitudinal evaluation of upper motor neuron burden scales in primary lateral sclerosis.

Authors:  Mary Kay Floeter; Tianxia Wu
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2020-07-13       Impact factor: 4.092

7.  Early diagnosis of amyotrophic lateral sclerosis by threshold tracking and conventional transcranial magnetic stimulation.

Authors:  Hatice Tankisi; Christina S-Z Nielsen; James Howells; Bülent Cengiz; Gintaute Samusyte; Martin Koltzenburg; Jakob U Blicher; Anette T Møller; Kirsten Pugdahl; Anders Fuglsang-Frederiksen; Mamede de Carvalho; Hugh Bostock
Journal:  Eur J Neurol       Date:  2021-07-22       Impact factor: 6.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.